Search Result

Results for "

CK1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Kinase (2) Akt (1) Apoptosis (8) Autophagy (2) Casein Kinase (64) CDK (8) Checkpoint Kinase (Chk) (1) Early 2 Factor (E2F) (1) ERK (1) Flavivirus (1) Glucose-6-Phosphate Isomerase (GPI) (1) GSK-3 (1) MALT1 (1) MDM-2/p53 (2) Molecular Glues (3) mTOR (1) p38 MAPK (9) PI3K (8) Porcupine (1) Ribosomal S6 Kinase (RSK) (2) SGK (2) VEGFR (1) Virus Protease (1) Wnt (7)
By Research Areas:	Cancer (41) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (5) Metabolic Disease (3) Neurological Disease (22)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114858

Epiblastin A	Casein Kinase	Cancer
Epiblastin A is an ATP competitive casein kinase 1 (CK1) inhibitor with IC₅₀s of 8.9, 0.5, and 4.7 µM for CK1α, CK1δ, and CK1 ɛ, respectively. Epiblastin A induces reprogramming of epiblast stem cells into embryonic stem cells by inhibition of CK1 .

HY-111820

CK1-IN-1	Casein Kinase p38 MAPK	Cardiovascular Disease
CK1-IN-1 (Compound 1c) is a casein kinase 1 (CK1) inhibitor with IC₅₀ values of 15 nM and 16 nM for CK1δ and CK1ε, respectively. CK1-IN-1 inhibits p38α MAPK with an IC₅₀ of 73 nM. CK1-IN-1 can be used to study cardiomyogenesis .

HY-158975

VRK1/CK1-IN-1	Casein Kinase	Cancer
VRK1/CK1-IN-1 (compound 36) is a dual inhibitor of vaccinia-related kinase 1 (VRK1) and casein kinase 1 (CK1), with the K_i of 37.9 nM for VRK1 and IC₅₀s of 17 nM and 15 nM for δ and ε isoforms of *CK1*, respectively .

HY-153866

CK1-IN-2	Casein Kinase	Cancer
CK1-IN-2 (compound Nr.4) is a potent *CK1* inhibitor with an IC₅₀ values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively .

HY-128433

CK1-IN-3	Casein Kinase	Neurological Disease
CK1-IN-3 (compound 51) is a AC1 inhibitor with an IC₅₀s 2.22 µM for CK-1δ .

HY-10324

D4476 5+ Cited Publications Casein Kinase I inhibitor	Casein Kinase Autophagy Apoptosis	Cancer
D4476 is a potent, selective and cell-permeable inhibitor of casein kinase 1(CK1) with an IC₅₀ value of 0.3 μM in vitro.

HY-103383

(R)-DRF053 dihydrochloride	CDK Casein Kinase	Neurological Disease Cancer
(R)-DRF053 dihydrochloride is a potent casein kinases 1 (CK1), CDK1/cyclin B and CDK5/p25 inhibitor with IC₅₀s of 14 nM, 220 nM and 80 nM, respectively. (R)-DRF053 dihydrochloride prevents the CK1-dependent production of amyloid-beta in a cell model .

HY-12470

PF-4800567 2 Publications Verification	Casein Kinase	Others
PF-4800567 is a potent and selective inhibitor of casein kinase 1? (CK1?), with an IC₅₀ of 32 nM, which is greater than 20-fold selectivity over CK1δ (IC₅₀, 711 nM).

HY-153866A

CK1-IN-2 hydrochloride	Casein Kinase	Cancer
CK1-IN-2 (compound Nr.4) hydrochloride is a potent *CK1* inhibitor with an IC₅₀ values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively .

HY-162756

CK1-IN-4	Casein Kinase	Neurological Disease
CK1-IN-4 (Compound 59) is an inhibitor for casein kinase *CK1δ* with IC₅₀ of 2.74 μM. CK1-IN-4 exhibits neuroprotective effect in Ethacrynic acid (HY-B1640)-treated SH-SY5Y cells .

HY-100114

TA-01	Casein Kinase p38 MAPK Autophagy	Cardiovascular Disease
TA-01 is a potent *CK1* and p38 MAPK inhibitor, with IC₅₀s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.

HY-12774

IC261 4 Publications Verification	Casein Kinase Apoptosis	Cancer
IC261 is a selective, ATP-competitive *CK1* inhibitor, with IC₅₀s of 1 μM, 1 μM, 16 μM for Ckiδ, Ckiε and Ckiα1, respectively.

HY-110052

TBCA 1 Publications Verification	Casein Kinase	Cancer
TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC₅₀ of 110 nM and a K_i of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .

HY-12470A

PF-4800567 hydrochloride	Casein Kinase	Cancer
PF-4800567 hydrochloride is a potent and selective inhibitor of?casein kinase?1? (CK1?), with an?IC₅₀?of 32 nM, which is greater than 20-fold selectivity over CK1δ (IC50, 711 nM). PF-4800567 hydrochloride is useful in probing unique roles between these two kinases in multiple signaling pathways .

HY-117857

MRT00033659	Casein Kinase Checkpoint Kinase (Chk) MDM-2/p53 Early 2 Factor (E2F)	Cancer
MRT00033659 is a potent broad-spectrum kinase inhibitor of *CK1* (IC₅₀=0.9 μM for CK1δ) and CHK1 (IC₅₀=0.23 μM). MRT00033659, a pyrazolo-pyridine analogue, induces p53 pathway activation and E2F-1 destabilisation .

HY-108442

JW67 1 Publications Verification	Wnt	Cancer
JW67 inhibits the canonical Wnt signaling with an IC₅₀ of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .

HY-15424

5-Iodotubercidin 5+ Cited Publications NSC 113939; 5-ITu	Adenosine Kinase	Cancer
5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC₅₀ of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .

HY-15424R

5-Iodotubercidin (Standard)	Adenosine Kinase	Cancer
5-Iodotubercidin (Standard) is the analytical standard of 5-Iodotubercidin. This product is intended for research and analytical applications. 5-Iodotubercidin (NSC 113939), an ATP mimetic, is a potent adenosine kinase inhibitor with an IC50 of 26 nM. 5-Iodotubercidin (NSC 113939) initiates glycogen synthesis in isolated hepatocytes by causing inactivation of phosphorylase and activation of glycogen synthase. 5-Iodotubercidin (NSC 113939) also inhibits CK1, insulin receptor tyrosine kinase, phosphorylase kinase, PKA, CK2, PKC and Haspin .

HY-W011109

CKI-7	Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK)	Cancer
CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC₅₀ of 6 μM and a K_i of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .

HY-133028

CKI-7 free base 1 Publications Verification	Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK)	Cancer
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC₅₀ of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .

HY-171301

*p38α MAPK/CK1δ inhibitor-1*	p38 MAPK Casein Kinase	Inflammation/Immunology
p38α MAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38α MAPK and *CK1δ* with IC₅₀s of 0.185 µM and 0.089 µM .

HY-171292

CK1δ-IN-9	Casein Kinase p38 MAPK	Others
CK1δ-IN-9 (Compound 8) is the inhibitor for casein kinase 1 that inhibits *CK1δ* with IC₅₀ of 1.4 nM. CK1δ-IN-9 inhibits p38α and p38β with IC₅₀ of 0.25 μM and 0.78 μM. CK1δ-IN-9 exhibits pharmacokinetic characteristics with a good oral bioavailability (70%) and a moderate clearance .

HY-W842364

CK1δ-IN-3	Casein Kinase	Neurological Disease
CK1δ-IN-3 (compound 376) is a casein kinase 1δ (CK1δ) inhibitor. CK1δ-IN-3 can be utilized in neurodegenerative disorders research .

HY-169713

CK1δ-IN-5	Casein Kinase	Neurological Disease
CK1δ-IN-5 (Compound 24) is a Casein kinase 1δ (CK1δ) inhibitor. CK1δ-IN-5 can be used in the research of neurodegenerative diseases .

HY-169556

CK1δ-IN-7	Casein Kinase	Neurological Disease
CK1δ-IN-7 (Compound 488) is the inhibitor for casein kinase 1δ (CK1δ) .

HY-169719

CK1δ-IN-6	Casein Kinase	Neurological Disease
CK1δ-IN-6 (Compound 303) is a Casein kinase 1δ inhibitor. CK1δ-IN-6 is promising for research of Alzheimer's disease .

HY-171298

CK1δ-IN-10	Casein Kinase	Neurological Disease Metabolic Disease Cancer
CK1δ-IN-10 (Compound 85) is the inhibitor for casein kinase 1 that inhibits *CK1δ* (CSNKID) with IC₅₀ of 0.255 μM .

HY-W840382

CK1δ-IN-8	Casein Kinase	Neurological Disease
CK1δ-IN-8 (Compound 429) is a *CK1δ* inhibitor that can be used in Alzheimer's disease research .

HY-100536

IWP-3	Wnt	Cancer
IWP-3 is an potent inhibitor of Wnt production with an IC₅₀ of 40 nM. IWP-3 inhibits Porcupine (Porcn) function thereby blocking palmitoylation of Wnt proteins. IWP-3 inhibits CK1γ3 and CK1ε only moderately and does not inhibit CK1α .

HY-18285

Longdaysin	Wnt Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits *CK1α, CK1δ, CDK7, and ERK2* with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .

HY-173494

GSK-3β/CK-1δ-IN-1	GSK-3 Casein Kinase	Cancer
GSK-3β/CK-1δ-IN-1 (8d) is a dual and blood-brain barrier penetrated GSK-3β / *CK-1δ* inhibitor, with IC₅₀ values of 0.77 μM for GSK-3β and 0.57 μM for CK-1δ, respectively. GSK-3β/CK-1δ-IN-1 (8d) can be used in the research for neuroblastoma .

HY-15490

PF-670462 dihydrochloride 5+ Cited Publications	Casein Kinase	Cancer
PF-670462 dihydrochloride is a potent and selective inhibitor of casein kinase (CK1ε and CK1δ), with IC₅₀s of 7.7 nM and 14 nM, respectively.

HY-100011

SR-3029 2 Publications Verification	Casein Kinase	Cancer
SR-3029 is a potent and ATP competitive *CK1δ* and *CK1ε* inhibitor, with IC₅₀s of 44 nM and 260 nM, respectively, and K_is of 97 nM for both kinases.

HY-171277

Casein kinase 1δ-IN-27	Casein Kinase p38 MAPK	Cancer
Casein kinase 1δ-IN-27 (Compound 8) is the inhibitor for casein kinase 1 that inhibits *CK1α, CK1δ, CK1ε, and p38α* with IC₅₀s of 22, 16.5, 9.41 and 14.8 nM, respectively. Casein kinase 1δ-IN-27 inhibits the DUX4 expression with an IC₅₀ of 10 nM .

HY-145939

BAY-888 BRD5846	Casein Kinase	Cancer
BAY-888 is a selective *CK1α/CSNK1A1* (casein kinase 1α) ATP-competitive inhibitor (IC₅₀: 4 nM@10 μM ATP; 63 nM@1 mM ATP). BAY-888 blocks the negative regulation of p53 and other signaling pathways by CK1α, induces apoptosis and inhibits proliferation of tumor cells. BAY-888 has shown inhibitory efficacy against cancers such as acute myeloid leukemia (AML) in PRISM barcoded cell line screening and can mimic the effects of shRNA-mediated CK1α knockdown. BAY-888 is primarily used for the development of anticancer drugs for p53 wild-type tumors and for the study of the mechanisms of CK1α-related signaling pathways .

HY-149292

SR-4133	Casein Kinase	Cancer
SR-4133 is a potent and highly *CK1ε* selective inhibitor with an IC₅₀ of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 .

HY-12443

PF-5006739	Casein Kinase	Neurological Disease
PF-5006739 is a potent and selective inhibitor of *CK1δ/ε* with IC₅₀s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner . PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity .

HY-171290

Casein kinase 1δ-IN-31	Casein Kinase p38 MAPK	Inflammation/Immunology
Casein kinase 1δ-IN-31 (Compound 16) is the inhibitor for casein kinase (CK) that inhibits *CK1α, CK1δ, and p38α* with IC₅₀s of 196, 17, and 18 nM, respectively. Casein kinase 1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with IC₅₀ of 1200 nM .

HY-155958

Casein kinase 1δ-IN-9	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-9 (compound 737) is a potent casein kinase 1δ (CK1δ/CK15) inhibitor. Casein kinase 1δ-IN-9 can be used for the research of neurodegenerative disorders such as Alzheimer's disease .

HY-153904

Casein kinase 1δ-IN-5	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-5 is a potent and selective protein kinase *CK-1δ* inhibitor with an IC₅₀ of 47 nM. Casein kinase 1δ-IN-5 shows neuroprotective and anti-inflammatory properties both in vitro. Casein kinase 1δ-IN-5 has the potential for neurodegenerative diseases research.

HY-162336

Casein kinase 1δ-IN-15	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-15 is an inhibitor for casein kinase 1 (CK1δ), with an IC₅₀ of 0.045 μM .

HY-10456

TAK-715 10+ Cited Publications	p38 MAPK Casein Kinase Wnt	Inflammation/Immunology
TAK-715 is an orally active and potent p38 MAPK inhibitor with IC₅₀s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .

HY-153905

Casein kinase 1δ-IN-6	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-6 is a potent and selective protein kinase *CK-1δ* inhibitor with an IC₅₀ of 23 nM. Casein kinase 1δ-IN-6 shows neuroprotective and anti-inflammatory properties both in vitro and in vivo. Casein kinase 1δ-IN-6 is a promising drug candidate and can be used for neurodegenerative diseases research.

HY-156040

Casein kinase 1δ-IN-10	Casein Kinase	Cancer
Casein kinase 1δ-IN-10 is a casein kinase 1δ (CK1δ) inhibitor (WO2012080729A2; compound 685) .

HY-121944

Ricinine	Casein Kinase Wnt	Others
Ricinine exhibits hepatoprotection in CCl4-induced liver damage. Ricinine is also a *CK1α* inhibitor, and may activate Wnt pathway .

HY-148455

Casein kinase 1δ-IN-3	Casein Kinase	Neurological Disease
Casein kinase 1δ-IN-3 (Compound 23a) is a casein kinase 1 delta (CK1d) inhibitor with a pIC₅₀ of 6.5376 M .

HY-171279

Casein kinase 1δ-IN-29	p38 MAPK Casein Kinase Apoptosis	Inflammation/Immunology
Casein kinase 1δ-IN-29 (Compound 18) is the inhibitor for p38α and casein kinase 1 that inhibits p38α, *CK1δ* and *CK1ε* with IC₅₀ of 0.041 µM, 0.005 µM and 0.447 µM, respectively. Casein kinase 1δ-IN-29 arrests cell cycle at subG1 phase, induces apoptosis in cell AC1-M88 .

HY-108907

SR-1277	Casein Kinase	Cancer
SR-1277 is a potent, selective and ATP competitive *CK1δ/ε* inhibitor, with IC₅₀s of 49 nM and 260 nM, respectively. SR-1277 also inhibits FLT3, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9/cyclin K, with IC₅₀s of 305 nM, 1340 nM, 311 nM and 109 nM, respectively. SR-1277 can be used for the research of cancer .

HY-120675

SSTC3 2 Publications Verification	Casein Kinase Wnt	Cancer
SSTC3 is a casein kinase 1α (CK1α) activator (K_d = 32 nM) that inhibits WNT signaling (EC₅₀ = 30 nM). SSTC3 exhibits minimal gastrointestinal toxicity compared to other classes of WNT inhibitors .

HY-171300

*p38α inhibitor* 8**	p38 MAPK Casein Kinase	Inflammation/Immunology
p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and *CK1δ* with IC₅₀ of 0.21 µM and 0.202 µM ^[1]>.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

CK1 inhibitor

Inhibitors & Agonists

NaturalProducts

Natural
Products